Are you over 18 and want to see adult content?
More Annotations
![A complete backup of helmholtz-berlin.de](https://www.archivebay.com/archive2/81eb26cd-0302-4416-b445-f3d03d02b369.png)
A complete backup of helmholtz-berlin.de
Are you over 18 and want to see adult content?
![A complete backup of ipokerdomino.org](https://www.archivebay.com/archive2/9b71fb4a-6d35-4922-84a9-3c6b83b087ad.png)
A complete backup of ipokerdomino.org
Are you over 18 and want to see adult content?
![A complete backup of lightspeedrender.com](https://www.archivebay.com/archive2/273f9b17-7a07-49b2-87ee-9ec6f6fd1413.png)
A complete backup of lightspeedrender.com
Are you over 18 and want to see adult content?
![A complete backup of yamashiro-spa.or.jp](https://www.archivebay.com/archive2/b8f90d84-6af4-4f2c-9355-50804403ffbf.png)
A complete backup of yamashiro-spa.or.jp
Are you over 18 and want to see adult content?
![A complete backup of philippinesbreakingnews.com](https://www.archivebay.com/archive2/3217524a-e3ef-4fdb-9a33-bd0f5f3946ba.png)
A complete backup of philippinesbreakingnews.com
Are you over 18 and want to see adult content?
![A complete backup of rainbowsbridge.com](https://www.archivebay.com/archive2/4cde43f8-57ce-425f-b64f-3277c2cd950c.png)
A complete backup of rainbowsbridge.com
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of nos.nl/l/2323884](https://www.archivebay.com/archive2/7e3ec39a-4e0f-4802-856c-91720cb21409.png)
A complete backup of nos.nl/l/2323884
Are you over 18 and want to see adult content?
![A complete backup of www.lexpress.fr/actualite/monde/oceanie/je-veux-me-suicider-le-cri-de-douleur-de-quaden-enfant-atteint-de-n](https://www.archivebay.com/archive2/8fdcb4da-aacb-4328-8415-16a089919b47.png)
A complete backup of www.lexpress.fr/actualite/monde/oceanie/je-veux-me-suicider-le-cri-de-douleur-de-quaden-enfant-atteint-de-n
Are you over 18 and want to see adult content?
![A complete backup of www.countypress.co.uk/sport/national/18255079.sydney-roosters-overcome-battling-st-helens-retain-world-club](https://www.archivebay.com/archive2/8919a985-a6f2-40ab-b154-48d8f203b5be.png)
A complete backup of www.countypress.co.uk/sport/national/18255079.sydney-roosters-overcome-battling-st-helens-retain-world-club
Are you over 18 and want to see adult content?
Text
Subscribe Now
XCONOMY: SANOFI PAYS KYMERA $150M TO KICK OFF PROTEIN Paris-based Sanofi (NASDAQ: SNY) agreed to pay Kymera $150 million upfront for the rights to develop a small molecule drug candidate the biotech has designed to GLAXOSMITHKLINE KEEPS ONCOLOGY 2.0 GROWTH PLANS ON TRACK Xconomy National — GlaxoSmithKline’s years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the XCONOMY: OYSTER POINT GETS $93M TO CLEAR UP DRY EYE WITH A Oyster Point, a Princeton, NJ startup led by former Ophthotech (NASDAQ: OPHT) executive Jeffrey Nau, has closed a $93 million Series B co-led by Invus and Flying L Partners. The cash will help XCONOMY: HOW TO BUILD A SUCCESSFUL INNOVATION ECOSYSTEM The Symposium on Science and Engineering Underpinning Sustainable Energies and Energy-Efficiency was an excellent opportunity to reflecton what I
XCONOMY: ELANCO IPO RAISES $1.5B AS THE ANIMAL HEALTH BIZ Elanco is now a standalone company after raising $1.5 billion in its stock market debut. Greenfield, IN-based Elanco (NYSE: ]) sold 62.9million shares at
XCONOMY: COO MANEESH ARORA LEAVING EXACT SCIENCES; MORE Xconomy Wisconsin —. Exact Sciences has made several additions to its leadership team in the past 18 months, but on Thursday the Madison, WI-based cancer test XCONOMY | BUSINESS, LIFE SCIENCES, AND TECHNOLOGY NEWSLIFE SCIENCESHEALTHTECHROBOTICS AND A.ISTARTUPSANDY SMITHDAVID JOHNSON Xconomy is a national news and events company dedicated to providing tech and biotech business leaders with timely, insightful, close-to-the-scene information about the personalities, companies THE NATIONAL XCONOMY AWARDS The 2020 National Xconomy Awards honors the top individuals, companies, and organizations that make the country's life sciences ecosystem the most vibrant and innovative in the world. XCONOMY: ROCHE, BLUEPRINT MEDICINES TEAM UP AGAIN IN $775M According to deal terms announced Tuesday, the companies will jointly commercialize the pill in the US. Roche gains rights to sell the drug globally, except for China. The Swiss pharmaceutical BOSTON-AREA ANGEL INVESTING GROUPS A directory of angel investing groups headquartered in New England. Xconomy on Demand We offer a number of ways to subscribe for free!Subscribe Now
XCONOMY: SANOFI PAYS KYMERA $150M TO KICK OFF PROTEIN Paris-based Sanofi (NASDAQ: SNY) agreed to pay Kymera $150 million upfront for the rights to develop a small molecule drug candidate the biotech has designed to GLAXOSMITHKLINE KEEPS ONCOLOGY 2.0 GROWTH PLANS ON TRACK Xconomy National — GlaxoSmithKline’s years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the XCONOMY: OYSTER POINT GETS $93M TO CLEAR UP DRY EYE WITH A Oyster Point, a Princeton, NJ startup led by former Ophthotech (NASDAQ: OPHT) executive Jeffrey Nau, has closed a $93 million Series B co-led by Invus and Flying L Partners. The cash will help XCONOMY: HOW TO BUILD A SUCCESSFUL INNOVATION ECOSYSTEM The Symposium on Science and Engineering Underpinning Sustainable Energies and Energy-Efficiency was an excellent opportunity to reflecton what I
XCONOMY: ELANCO IPO RAISES $1.5B AS THE ANIMAL HEALTH BIZ Elanco is now a standalone company after raising $1.5 billion in its stock market debut. Greenfield, IN-based Elanco (NYSE: ]) sold 62.9million shares at
XCONOMY: COO MANEESH ARORA LEAVING EXACT SCIENCES; MORE Xconomy Wisconsin —. Exact Sciences has made several additions to its leadership team in the past 18 months, but on Thursday the Madison, WI-based cancer test GLAXOSMITHKLINE KEEPS ONCOLOGY 2.0 GROWTH PLANS ON TRACK Xconomy National — GlaxoSmithKline’s years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the XCONOMY: ROCHE, BLUEPRINT MEDICINES TEAM UP AGAIN IN $775M According to deal terms announced Tuesday, the companies will jointly commercialize the pill in the US. Roche gains rights to sell the drug globally, except for China. The Swiss pharmaceutical XCONOMY: ABBVIE EXITS EDITAS ALLIANCE, PRUNING ANOTHER Xconomy Boston —. AbbVie has terminated a research partnership with Editas Medicines, returning to the biotech rights to an experimental gene-editing treatment. It’s the second geneticSARAH DE CRESCENZO
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience XCONOMY: VOYAGER THERAPEUTICS CHIEF OPERATING OFFICER Xconomy Boston — . Gene therapy developer Voyager Therapeutics (NASDAQ: VYGR) has lost its chief operating officer.Matthew Ottmer,who held
XCONOMY: ALEXION PHARMA BOOSTS BLOOD DRUG LINEUP WITH $1 Xconomy Boston — . Alexion Pharmaceuticals has agreed to buy Portola Pharmaceuticals in a $1.4 billion deal that brings it a first-in-class therapy for treating life-threatening bleeding XCONOMY: WAKE FOREST INSTITUTE ADVANCING BIOPRINTER TECH Xconomy Raleigh-Durham — . In the not too distant future, one of the most important pieces of equipment for treating injured soldiers at a combat hospital could be a printer. XCONOMY: THE MEMO THAT SPAWNED MICROSOFT RESEARCH Microsoft Research, the central research arm of that tech giant of the northwest, was founded in September 1991. This is the prehistory. Withthe
XCONOMY: HAMBURGERS, COFFEE, GUITARS, AND CARS: A REPORT The prototype Momentum Machines hamburger-making robot. The prototype is a miniature assembly line, with one conveyor that carries pattiesthrough a
XCONOMY: FOUR REASONS TO ENCOURAGE EMPLOYEES TO TAKE SMART The economic downturn and subsequent market volatility have made risk into a four-letter word. Employees, in particular, are growingincreasingly
XCONOMY | BUSINESS, LIFE SCIENCES, AND TECHNOLOGY NEWSLIFE SCIENCESHEALTHTECHROBOTICS AND A.ISTARTUPSANDY SMITHDAVID JOHNSON Xconomy is a national news and events company dedicated to providing tech and biotech business leaders with timely, insightful, close-to-the-scene information about the personalities, companies THE NATIONAL XCONOMY AWARDS The 2020 National Xconomy Awards honors the top individuals, companies, and organizations that make the country's life sciences ecosystem the most vibrant and innovative in the world. XCONOMY: ROCHE, BLUEPRINT MEDICINES TEAM UP AGAIN IN $775M According to deal terms announced Tuesday, the companies will jointly commercialize the pill in the US. Roche gains rights to sell the drug globally, except for China. The Swiss pharmaceutical BOSTON-AREA ANGEL INVESTING GROUPS A directory of angel investing groups headquartered in New England. Xconomy on Demand We offer a number of ways to subscribe for free!Subscribe Now
XCONOMY: SANOFI PAYS KYMERA $150M TO KICK OFF PROTEIN Paris-based Sanofi (NASDAQ: SNY) agreed to pay Kymera $150 million upfront for the rights to develop a small molecule drug candidate the biotech has designed to GLAXOSMITHKLINE KEEPS ONCOLOGY 2.0 GROWTH PLANS ON TRACK Xconomy National — GlaxoSmithKline’s years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the XCONOMY: OYSTER POINT GETS $93M TO CLEAR UP DRY EYE WITH A Oyster Point, a Princeton, NJ startup led by former Ophthotech (NASDAQ: OPHT) executive Jeffrey Nau, has closed a $93 million Series B co-led by Invus and Flying L Partners. The cash will help XCONOMY: HOW TO BUILD A SUCCESSFUL INNOVATION ECOSYSTEM The Symposium on Science and Engineering Underpinning Sustainable Energies and Energy-Efficiency was an excellent opportunity to reflecton what I
XCONOMY: ELANCO IPO RAISES $1.5B AS THE ANIMAL HEALTH BIZ Elanco is now a standalone company after raising $1.5 billion in its stock market debut. Greenfield, IN-based Elanco (NYSE: ]) sold 62.9million shares at
XCONOMY: COO MANEESH ARORA LEAVING EXACT SCIENCES; MORE Xconomy Wisconsin —. Exact Sciences has made several additions to its leadership team in the past 18 months, but on Thursday the Madison, WI-based cancer test XCONOMY | BUSINESS, LIFE SCIENCES, AND TECHNOLOGY NEWSLIFE SCIENCESHEALTHTECHROBOTICS AND A.ISTARTUPSANDY SMITHDAVID JOHNSON Xconomy is a national news and events company dedicated to providing tech and biotech business leaders with timely, insightful, close-to-the-scene information about the personalities, companies THE NATIONAL XCONOMY AWARDS The 2020 National Xconomy Awards honors the top individuals, companies, and organizations that make the country's life sciences ecosystem the most vibrant and innovative in the world. XCONOMY: ROCHE, BLUEPRINT MEDICINES TEAM UP AGAIN IN $775M According to deal terms announced Tuesday, the companies will jointly commercialize the pill in the US. Roche gains rights to sell the drug globally, except for China. The Swiss pharmaceutical BOSTON-AREA ANGEL INVESTING GROUPS A directory of angel investing groups headquartered in New England. Xconomy on Demand We offer a number of ways to subscribe for free!Subscribe Now
XCONOMY: SANOFI PAYS KYMERA $150M TO KICK OFF PROTEIN Paris-based Sanofi (NASDAQ: SNY) agreed to pay Kymera $150 million upfront for the rights to develop a small molecule drug candidate the biotech has designed to GLAXOSMITHKLINE KEEPS ONCOLOGY 2.0 GROWTH PLANS ON TRACK Xconomy National — GlaxoSmithKline’s years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the XCONOMY: OYSTER POINT GETS $93M TO CLEAR UP DRY EYE WITH A Oyster Point, a Princeton, NJ startup led by former Ophthotech (NASDAQ: OPHT) executive Jeffrey Nau, has closed a $93 million Series B co-led by Invus and Flying L Partners. The cash will help XCONOMY: HOW TO BUILD A SUCCESSFUL INNOVATION ECOSYSTEM The Symposium on Science and Engineering Underpinning Sustainable Energies and Energy-Efficiency was an excellent opportunity to reflecton what I
XCONOMY: ELANCO IPO RAISES $1.5B AS THE ANIMAL HEALTH BIZ Elanco is now a standalone company after raising $1.5 billion in its stock market debut. Greenfield, IN-based Elanco (NYSE: ]) sold 62.9million shares at
XCONOMY: COO MANEESH ARORA LEAVING EXACT SCIENCES; MORE Xconomy Wisconsin —. Exact Sciences has made several additions to its leadership team in the past 18 months, but on Thursday the Madison, WI-based cancer test GLAXOSMITHKLINE KEEPS ONCOLOGY 2.0 GROWTH PLANS ON TRACK Xconomy National — GlaxoSmithKline’s years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the XCONOMY: ROCHE, BLUEPRINT MEDICINES TEAM UP AGAIN IN $775M According to deal terms announced Tuesday, the companies will jointly commercialize the pill in the US. Roche gains rights to sell the drug globally, except for China. The Swiss pharmaceutical XCONOMY: ABBVIE EXITS EDITAS ALLIANCE, PRUNING ANOTHER Xconomy Boston —. AbbVie has terminated a research partnership with Editas Medicines, returning to the biotech rights to an experimental gene-editing treatment. It’s the second geneticSARAH DE CRESCENZO
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience XCONOMY: VOYAGER THERAPEUTICS CHIEF OPERATING OFFICER Xconomy Boston — . Gene therapy developer Voyager Therapeutics (NASDAQ: VYGR) has lost its chief operating officer.Matthew Ottmer,who held
XCONOMY: ALEXION PHARMA BOOSTS BLOOD DRUG LINEUP WITH $1 Xconomy Boston — . Alexion Pharmaceuticals has agreed to buy Portola Pharmaceuticals in a $1.4 billion deal that brings it a first-in-class therapy for treating life-threatening bleeding XCONOMY: WAKE FOREST INSTITUTE ADVANCING BIOPRINTER TECH Xconomy Raleigh-Durham — . In the not too distant future, one of the most important pieces of equipment for treating injured soldiers at a combat hospital could be a printer. XCONOMY: THE MEMO THAT SPAWNED MICROSOFT RESEARCH Microsoft Research, the central research arm of that tech giant of the northwest, was founded in September 1991. This is the prehistory. Withthe
XCONOMY: HAMBURGERS, COFFEE, GUITARS, AND CARS: A REPORT The prototype Momentum Machines hamburger-making robot. The prototype is a miniature assembly line, with one conveyor that carries pattiesthrough a
XCONOMY: FOUR REASONS TO ENCOURAGE EMPLOYEES TO TAKE SMART The economic downturn and subsequent market volatility have made risk into a four-letter word. Employees, in particular, are growingincreasingly
XCONOMY | BUSINESS, LIFE SCIENCES, AND TECHNOLOGY NEWSLIFE SCIENCESHEALTHTECHROBOTICS AND A.ISTARTUPSANDY SMITHDAVID JOHNSON Xconomy is a national news and events company dedicated to providing tech and biotech business leaders with timely, insightful, close-to-the-scene information about the personalities, companies THE NATIONAL XCONOMY AWARDS The 2020 National Xconomy Awards honors the top individuals, companies, and organizations that make the country's life sciences ecosystem the most vibrant and innovative in the world. XCONOMY: SANOFI PAYS KYMERA $150M TO KICK OFF PROTEIN Paris-based Sanofi (NASDAQ: SNY) agreed to pay Kymera $150 million upfront for the rights to develop a small molecule drug candidate the biotech has designed to XCONOMY: ABBVIE EXITS EDITAS ALLIANCE, PRUNING ANOTHER Xconomy Boston —. AbbVie has terminated a research partnership with Editas Medicines, returning to the biotech rights to an experimental gene-editing treatment. It’s the second genetic BOSTON-AREA ANGEL INVESTING GROUPS A directory of angel investing groups headquartered in New England. Xconomy on Demand We offer a number of ways to subscribe for free!Subscribe Now
XCONOMY: SMA MOMENT: WILL GENE THERAPY SHIFT TREATMENTAUTHOR: BEN FIDLERNEW SMA TREATMENTSMA TYPE 1 TREATMENTSMA FOUNDATIONSMA INVESTMENT TERMSMA INVESTMENT VEHICLESMA VS MUTUAL FUND Xconomy National — . This is a big moment for people diagnosed with spinal muscular atrophy, or SMA, a rare and potentially lethal genetic disorder that destroys muscles. XCONOMY: DISCOVERY LABS CONVERTS EX-GSK KING OF PRUSSIADISCOVERY LABS KING OF PRUSSIATHE DISCOVERY LABS KING OF PRUSSIAHOMES FOR SALE KING OF PRUSSIA PAKING OF PRUSSIA BREAKING NEWSZILLOW KING OF PRUSSIAKING OF PRUSSIA MALL DIRECTORY In April 2018, GlaxoSmithKline (NYSE: GSK) sold its R&D campus in King of Prussia, PA, to private Philadelphia-based life science and real estate investment company MLP Ventures for about $50 XCONOMY: HOW TO BUILD A SUCCESSFUL INNOVATION ECOSYSTEM The Symposium on Science and Engineering Underpinning Sustainable Energies and Energy-Efficiency was an excellent opportunity to reflecton what I
XCONOMY: OYSTER POINT GETS $93M TO CLEAR UP DRY EYE WITH AOYSTER POINT HOTELOYSTER POINT PHARMACEUTICALS STOCKOYSTER POINT THERAPEUTICSOYSTER BAY RESORT SEBASTIAN FLORIDAOYSTER INC Oyster Point, a Princeton, NJ startup led by former Ophthotech (NASDAQ: OPHT) executive Jeffrey Nau, has closed a $93 million Series B co-led by Invus and Flying L Partners. The cash will help XCONOMY: COO MANEESH ARORA LEAVING EXACT SCIENCES; MORE Xconomy Wisconsin —. Exact Sciences has made several additions to its leadership team in the past 18 months, but on Thursday the Madison, WI-based cancer test XCONOMY | BUSINESS, LIFE SCIENCES, AND TECHNOLOGY NEWSLIFE SCIENCESHEALTHTECHROBOTICS AND A.ISTARTUPSANDY SMITHDAVID JOHNSON Xconomy is a national news and events company dedicated to providing tech and biotech business leaders with timely, insightful, close-to-the-scene information about the personalities, companies THE NATIONAL XCONOMY AWARDS The 2020 National Xconomy Awards honors the top individuals, companies, and organizations that make the country's life sciences ecosystem the most vibrant and innovative in the world. XCONOMY: SANOFI PAYS KYMERA $150M TO KICK OFF PROTEIN Paris-based Sanofi (NASDAQ: SNY) agreed to pay Kymera $150 million upfront for the rights to develop a small molecule drug candidate the biotech has designed to XCONOMY: ABBVIE EXITS EDITAS ALLIANCE, PRUNING ANOTHER Xconomy Boston —. AbbVie has terminated a research partnership with Editas Medicines, returning to the biotech rights to an experimental gene-editing treatment. It’s the second genetic BOSTON-AREA ANGEL INVESTING GROUPS A directory of angel investing groups headquartered in New England. Xconomy on Demand We offer a number of ways to subscribe for free!Subscribe Now
XCONOMY: SMA MOMENT: WILL GENE THERAPY SHIFT TREATMENTAUTHOR: BEN FIDLERNEW SMA TREATMENTSMA TYPE 1 TREATMENTSMA FOUNDATIONSMA INVESTMENT TERMSMA INVESTMENT VEHICLESMA VS MUTUAL FUND Xconomy National — . This is a big moment for people diagnosed with spinal muscular atrophy, or SMA, a rare and potentially lethal genetic disorder that destroys muscles. XCONOMY: DISCOVERY LABS CONVERTS EX-GSK KING OF PRUSSIADISCOVERY LABS KING OF PRUSSIATHE DISCOVERY LABS KING OF PRUSSIAHOMES FOR SALE KING OF PRUSSIA PAKING OF PRUSSIA BREAKING NEWSZILLOW KING OF PRUSSIAKING OF PRUSSIA MALL DIRECTORY In April 2018, GlaxoSmithKline (NYSE: GSK) sold its R&D campus in King of Prussia, PA, to private Philadelphia-based life science and real estate investment company MLP Ventures for about $50 XCONOMY: HOW TO BUILD A SUCCESSFUL INNOVATION ECOSYSTEM The Symposium on Science and Engineering Underpinning Sustainable Energies and Energy-Efficiency was an excellent opportunity to reflecton what I
XCONOMY: OYSTER POINT GETS $93M TO CLEAR UP DRY EYE WITH AOYSTER POINT HOTELOYSTER POINT PHARMACEUTICALS STOCKOYSTER POINT THERAPEUTICSOYSTER BAY RESORT SEBASTIAN FLORIDAOYSTER INC Oyster Point, a Princeton, NJ startup led by former Ophthotech (NASDAQ: OPHT) executive Jeffrey Nau, has closed a $93 million Series B co-led by Invus and Flying L Partners. The cash will help XCONOMY: COO MANEESH ARORA LEAVING EXACT SCIENCES; MORE Xconomy Wisconsin —. Exact Sciences has made several additions to its leadership team in the past 18 months, but on Thursday the Madison, WI-based cancer test GLAXOSMITHKLINE KEEPS ONCOLOGY 2.0 GROWTH PLANS ON TRACK Xconomy National — GlaxoSmithKline’s years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the XCONOMY: DISCOVERY LABS CONVERTS EX-GSK KING OF PRUSSIA In April 2018, GlaxoSmithKline (NYSE: GSK) sold its R&D campus in King of Prussia, PA, to private Philadelphia-based life science and real estate investment company MLP Ventures for about $50 XCONOMY: ALNYLAM GETS QUICK FDA OK FOR SECOND RNAI RARE Xconomy Boston — An Alnylam Pharmaceuticals drug developed to treat a rare, inherited metabolic disorder won FDA approval on XCONOMY: ESPERION’S FDA-APPROVED CHOLESTEROL DRUG PRICED The FDA approved the Esperion drug, bempedoic acid (Nexletol), late Friday. On Monday, Mayleben said the drug will cost patients even less than he had projected. A patient’s $10 out-of-pocket XCONOMY: VOYAGER THERAPEUTICS CHIEF OPERATING OFFICER Xconomy Boston — . Gene therapy developer Voyager Therapeutics (NASDAQ: VYGR) has lost its chief operating officer.Matthew Ottmer,who held
XCONOMY: BIOINTERVENE RAISES $30M TO MOVE NERVE PAIN DRUG Now the San Diego-based biotech has $30 million and a chief scientific officer, Charles Cohen, to guide its lead compound, BIO-205, intohuman
XCONOMY: EMENDO BIOTHERAPEUTICS NABS $61M FOR “NEXT Xconomy New York — Emendo Biotherapeutics, a company aiming to apply CRISPR gene editing to awider range of
XCONOMY: FOUR REASONS TO ENCOURAGE EMPLOYEES TO TAKE SMART The economic downturn and subsequent market volatility have made risk into a four-letter word. Employees, in particular, are growingincreasingly
XCONOMY: FDA APPROVES ELANCO CATTLE DRUG, THE FIRST FOR The FDA has approved an Elanco (NYSE: ELAN) drug developed to reduce the ammonia gas released from cattle manure. The agency says itsTuesday decision on
XCONOMY: E-COMMERCE FIRM BLACK RIFLE COFFEE HAS EXPANSION In the meantime, Black Rifle Coffee is moving in March to Texas, to a new headquarters in the Austin-San Antonio area. Hafer says the Interstate 35 corridor in that region is home to one of the*
Subscribe __e
Xconomy’s Digital Events →▾
*
XCONOMY NATIONAL
* Our
Regions
* National ›
*
SANOFI, PFIZER & BRISTOL DRUGS AMONG THE 12 APPROVALS TO LOOK OUT FORIN Q4
View More in National ›* Europe ›
*
FDA PANEL VOTE WEIGHS IN FAVOR OF ALKERMES PSYCH DRUG, WITH CAVEATS View More in Europe ›* Boston ›
*
VERTEX STOPS TEST OF RARE DISEASE DRUG, DIMMING PIPELINE PROSPECTS View More in Boston › * Boulder/Denver ›*
BIO LAUNCHES 'BIOTECH VOTES' CAMPAIGN TO ENCOURAGE REGISTRATION ANDINFORMED VOTING
View More in Boulder/Denver › * Detroit/Ann Arbor ›*
BIO LAUNCHES 'BIOTECH VOTES' CAMPAIGN TO ENCOURAGE REGISTRATION ANDINFORMED VOTING
View More in Detroit/Ann Arbor ›* Indiana ›
*
BIO LAUNCHES 'BIOTECH VOTES' CAMPAIGN TO ENCOURAGE REGISTRATION ANDINFORMED VOTING
View More in Indiana ›* New York ›
*
“OPIOID STACKING” CONCERNS LEAD FDA TO REJECT AVENUE THERAPEUTICSDRUG
View More in New York ›* Philadelphia ›
*
BIO LAUNCHES 'BIOTECH VOTES' CAMPAIGN TO ENCOURAGE REGISTRATION ANDINFORMED VOTING
View More in Philadelphia › * Raleigh-Durham ›*
BIO LAUNCHES 'BIOTECH VOTES' CAMPAIGN TO ENCOURAGE REGISTRATION ANDINFORMED VOTING
View More in Raleigh-Durham ›* San Diego ›
*
DESPITE PHASE 2 FAILURE, GOSSAMER BIO SEES A PATH FOR DRUG IN ASTHMA View More in San Diego ›* San Francisco ›
*
BIO LAUNCHES 'BIOTECH VOTES' CAMPAIGN TO ENCOURAGE REGISTRATION ANDINFORMED VOTING
View More in San Francisco ›* Seattle ›
*
BIO LAUNCHES 'BIOTECH VOTES' CAMPAIGN TO ENCOURAGE REGISTRATION ANDINFORMED VOTING
View More in Seattle ›* Texas ›
*
BIO LAUNCHES 'BIOTECH VOTES' CAMPAIGN TO ENCOURAGE REGISTRATION ANDINFORMED VOTING
View More in Texas ›* Wisconsin ›
*
BIO LAUNCHES 'BIOTECH VOTES' CAMPAIGN TO ENCOURAGE REGISTRATION ANDINFORMED VOTING
View More in Wisconsin ›* Topic
Channels
* Life Sciences›
View More in Life Sciences ›* Healthtech›
View More in Healthtech › * Robotics and A.I.› View More in Robotics and A.I. ›* Startups›
View More in Startups ›* Our
Events
* All Xconomy Events ›* Xconomy
Insight
TOP STORIES
*
VERTEX STOPS TEST OF RARE DISEASE DRUG, DIMMING PIPELINE PROSPECTS*
ROCHE ENLISTS DYNO TO BRING AI TO NEXT-GENERATION LIVER, CNS GENETHERAPIES
*
SQZ BIOTECH LINES UP AN IPO ON THE NYSE TO FUND CELL THERAPY R&D*
FDA PANEL VOTE WEIGHS IN FAVOR OF ALKERMES PSYCH DRUG, WITH CAVEATSLATEST POSTS
*
SANOFI, PFIZER & BRISTOL DRUGS AMONG THE 12 APPROVALS TO LOOK OUT FORIN Q4
The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in... Read more » ALEX SHIMMINGS 10/15/20*
VERTEX STOPS TEST OF RARE DISEASE DRUG, DIMMING PIPELINE PROSPECTS Vertex Pharmaceuticals is halting work on an experimental drug for a rare protein deficiency after safety problems were reported in Phase 2 testing. The study was evaluating the small molecule, VX-814, as a treatment for alpha-1 antitrypsin deficiency, which can lead... Read more » FRANK VINLUAN 10/15/20*
CODIAK BIO’S IPO BRINGS IN $82M AS EXOSOME CLINICAL TRIALS BEGIN Codiak BioSciences now has $82.5 million to fund clinical tests of a new class of medicines based on exosomes, tiny bubbles formed by cells that the company harnesses to carry therapeutic cargo. Late Tuesday, Codiak priced its offering of 5.5 million... Read more » FRANK VINLUAN 10/14/20*
ROCHE ENLISTS DYNO TO BRING AI TO NEXT-GENERATION LIVER, CNS GENETHERAPIES
Roche made a splash with its acquisition of Spark Therapeutics, whose Luxturna, a gene therapy for an inherited form of vision loss, was the first such therapy to win FDA approval. Now the Swiss pharmaceutical giant is looking to bolster its... Read more » FRANK VINLUAN 10/14/20*
DESPITE PHASE 2 FAILURE, GOSSAMER BIO SEES A PATH FOR DRUG IN ASTHMA Gossamer Bio’s lead drug, an experimental treatment for asthma and allergies, has failed in two mid-stage clinical trials but the biotech sees enough in the data to pursue further development in a severe form of asthma and it wants to talk... Read more » FRANK VINLUAN 10/13/20*
SQZ BIOTECH LINES UP AN IPO ON THE NYSE TO FUND CELL THERAPY R&D SQZ Biotechnologies, which already has an alliance with Roche focused on developing new cancer cell therapies, is now looking to sell shares to the public to finance its research of potential new treatments for both cancer and infectious disease.In paperwork
...
Read more »
FRANK VINLUAN 10/12/20*
“OPIOID STACKING” CONCERNS LEAD FDA TO REJECT AVENUE THERAPEUTICSDRUG
An opioid that Avenue Therapeutics reformulated for treating post-surgical pain in hospital settings has been rejected by the FDA due to safety concerns. The Avenue (NASDAQ: ATXI ) drug is an intravenous formulation of tramadol, an opioid that first reachedthe... Read more »
FRANK VINLUAN 10/12/20*
FDA PANEL VOTE WEIGHS IN FAVOR OF ALKERMES PSYCH DRUG, WITH CAVEATS An Alkermes antipsychotic treatment designed to offer the benefits of a commonly prescribed medicine, but without the weight gain side effect, won the backing of an FDA advisory committee on Friday. But even some of the panel members who supported the... Read more » FRANK VINLUAN 10/9/20*
BIO ROUNDUP: CRISPR KUDOS, BRISTOL MYERS’S BUY, RNAI ALLIANCE &MORE
It’s October: a time of days growing shorter, leaves changing color, and phone calls in the wee hours that rouse scientists from slumber notifying them they’ve won the highest honor in their fields. This week, the 2020 Nobel Prize in physiology...
Read more »
FRANK VINLUAN 10/9/20*
BIOGEN’S ADCOMM MEETING WILL TEST FDA’S “SUBSTANTIAL EVIDENCE” FLEXIBILITY A US Food and Drug Administration advisory committee meeting on Biogen, Inc.’s Alzheimer’s drug aducanumab will offer some insight into the amount of flexibility the agency and its external experts are willing to exercise for neurodegenerative diseases with high unmet need,... Read more »SUE SUTTER 10/8/20
*
IN RNAI MOVE, TAKEDA FRONTS $300M TO TEAM UP ON ARROWHEAD LIVER DRUG Arrowhead Pharmaceuticals’ gene silencing treatment for a rare liver disease will move through the regulatory process and potential commercialization with the muscle of Takeda Pharmaceutical behind it. Takeda (NYSE: TAK ) has agreed to pay $300 million up front in a... Read more » FRANK VINLUAN 10/8/20*
BIO LAUNCHES ‘BIOTECH VOTES’ CAMPAIGN TO ENCOURAGE REGISTRATIONAND INFORMED VOTING
Science is the way out of this pandemic—and scientific breakthroughs are on the ballot on November 3. To help you get ready for Election Day, BIO’s initiative Biotech Votes has resources to help you get registered and get informed. First, make... Read more »EDITORS 10/8/20
*
SCRIBE THERAPEUTICS SETS OUT TO WRITE CRISPR GENE EDITING’S NEXTCHAPTER
The first generation of CRISPR-based therapies showed how the technology can edit DNA, making genetic fixes to unwanted mutations. But those treatments use the CRISPR system as scientists found it in nature, which means it still has limitations when applied to... Readmore »
FRANK VINLUAN 10/6/20Load More News ›
*
FEDERATION BIO BAGS $50M TO ENGINEER NEW APPROACH TO MICROBIOME DRUGS Scientists at microbiome therapy developers often talk about the importance of community, how the bugs in our gut act in concert in addition to their individual roles. That’s important for microbiome health and for microbe-based therapies, says Emily Drabant Conley, CEOof... Read more »
FRANK VINLUAN 10/6/20*
BRISTOL MYERS TO BUY MYOKARDIA, FDA-READY HEART DISEASE DRUG FOR$13.1B
Bristol Myers Squibb is bolstering its cardiovascular drug lineup with a $13.1 billion deal to acquire MyoKardia, a company whose experimental therapy for a rare type of heart disease is on track for an FDA submission and is projected to become... Read more » FRANK VINLUAN 10/5/20*
BRISTOL MYERS’S HIRAWAT ON PIPELINE PROGRESS, CLINICAL TRIALDIVERSITY
As the one-year anniversary of Bristol-Myers Squibb Company’s $74bn acquisition of Celgene Corporation approaches, Scrip spoke with chief medical officer Samit Hirawat about the big pharma’s achievements during a challenging period in which the COVID-19 pandemic threatened to derail clinical trials... Read more » MANDY JACKSON 10/2/20*
BIO ROUNDUP: MESO’S MISS, PFIZER’S CANCER BET, VACCINE PROMISE &MORE
Amid the bombast of Tuesday’s presidential debate, viewers caught some discussion about the response to the coronavirus pandemic and efforts to develop a COVID-19 vaccine. In the crosstalk, the president made an unsupported claim that we are weeks away from having... Readmore »
FRANK VINLUAN 10/2/20*
FDA LIFTS SOLID BIO CLINICAL HOLD, DUCHENNE STUDY CLEARED TO RESUME Solid Biosciences has answered the FDA’s outstanding questions about its Duchenne muscular gene therapy, clearing a clinical trial to nowresume
after patient complications last year led the agency to halt the studyfor a second time.
Cambridge, MA-based Solid Bio... Read more » FRANK VINLUAN 10/1/20*
GENFIT RESTRUCTURING CUTS STAFF BY 40%, CREATES TWO NEW SUBSIDIARIES Genfit is halting all work on its lead drug in the fatty liver disorder nonalcoholic steatohepatitis (NASH) and implementing a corporate restructuring that will cut 40 percent of its staff, splitting the remaining workforce into... Read more » FRANK VINLUAN 10/1/20*
PFIZER PUMPS $200M INTO CSTONE FOR RIGHTS TO PD-L1 CANCER DRUG INCHINA
CStone Pharmaceuticals has touted its experimental drug sugemalimab as potentially the best in its class of cancer immunotherapies. Pfizer is placing a bet on that promise by making a $200 million equity investment in CStone for rights to that drug in... Read more » FRANK VINLUAN 9/30/20*
WITH PHASE 2 DATA IN HAND, OVID EYES MULTIPLE PIVOTAL TRIALS FOREPILEPSY DRUG
Ovid Therapeutics and Takeda Pharmaceutical joined forces three years ago to develop a small molecule into a potential epilepsy drug. That research is starting to pay off as the companies now look ahead to pivotal studies testing that compound in several... Read more » FRANK VINLUAN 9/30/20*
ORPHAZYME STOCK SALE REAPS $83M AS NEIMANN-PICK DRUG REVIEW BEGINS Orphazyme has fresh cash from the sale of shares in the US and Europe, which will support its lead rare disease drug through regulatory review and, if approved, a launch. But the drug fell short in key clinical trial measures, raising... Read more » FRANK VINLUAN 9/29/20Load More News ›
*
PRAXIS PRECISION MEDICINES LEADS WAY AS THREE MORE BIOTECHS PREP IPOS Praxis Precision Medicines kept mostly quiet about its research on central nervous system disorder (CNS) drugs until May, when it emerged from stealth and revealed $100 million in cumulative financing.
Now the company is aiming to raise about that amount... Read more » FRANK VINLUAN 9/28/20*
GALECTO PICKS UP $64M AS PLANS FOR FIBROSIS CLINICAL TRIALS MOVEFORWARD
Had things turned out differently, scientists at Galecto might be watching their idiopathic pulmonary fibrosis drug candidate develop in the hands of a big pharmaceutical company. But Bristol Myers Squibb passed on its option to acquire Galecto leaving the biotech to... Readmore »
FRANK VINLUAN 9/25/20*
BIO ROUNDUP: GRAIL ACQUISITION, LIBRA’S LAUNCH, TAU TRIAL RESULTS &MORE
In biotech, you can go home again. Four years ago, Illumina spun out cancer diagnostics startup Grail. This week, the gene sequencing giant announced it is acquiring Grail in an $8 billion cash and stock deal. Grail set out with the... Read more » FRANK VINLUAN 9/25/20*
COMBINED THERAPEUTICS INC WINS $250,000 MILLIPORESIGMA ADVANCEBIOTECH GRANT
MilliporeSigma has awarded MIT spin-out Combined Therapeutics Inc. as the winner of its 2020 North America Advance Biotech Grant. Combined Therapeutics Inc (CTx) is an early stage startup developing next generation virotherapies targeted with nucleic acids. The pre-clinical biotech aims to... Read more »EDITORS 9/25/20
*
MONTE ROSA RAISES $96M FOR “GLUE-BASED” PROTEIN DEGRADING DRUGS Many drugs work by binding to a protein and blocking it. Technology for eliminating disease-causing proteins altogether remains experimental, but this approach has gained ground in the past year with hundreds of millions of dollars raised and compounds advanced into clinical... Read more » FRANK VINLUAN 9/24/20*
AND THE 2020 NATIONAL XCONOMY AWARDS WINNERS ARE… Congratulations to all the finalists and winners! This year we received over 600 nominations across 10 award categories. Each nomination was carefully reviewed and ranked by the Xconomy editorial staff yielding 40 finalists. All have made unique, game-changing contributions that improve... Read more »EDITORS 9/24/20
*
LIBRA STRIKES A BALANCE WITH APPROACH TO ALS AND OTHER NEURODISORDERS
Amyotrophic lateral sclerosis (ALS) has no cure and few available treatments but the past decade has revealed new knowledge about the pathology of the disease. Libra Therapeutics is turning that research into potential therapies, and it now has $29 million to... Read more FRANK VINLUAN 9/23/20*
TAU-TARGETING ALZHEIMER’S DRUG FROM AC IMMUNE, ROCHE FAILS IN PHASE2
An Alzheimer’s disease drug from partners AC Immune and Roche has failed a mid-stage clinical trial, adding another compound to the list of experimental therapies that have fallen short of demonstrating that they can treat the neurodegenerative disorder. The drug, semorinemab,... Read more » FRANK VINLUAN 9/23/20Read More Posts ›
XCONOMIST FORUMEXPERT INSIGHT AND OPINION*
CLINICAL TRIAL DIVERSITY ISN’T JUST A MORAL ISSUE–IT’S A SCIENTIFIC IMPERATIVELIZ BEATTY
*
CREATING CONSISTENT VALUE IN BIOTECH WITHOUT DILUTING STAKEHOLDERSALEXIS PEYROLES
*
LAX APPROVAL REQUIREMENTS YIELD BLOCKBUSTERS THAT DON’T WORKANDY SMITH
*
DIGITAL HEALTH SURVIVORS & INNOVATIVE INCUMBENTS MUST TEAM UP FORTRUE DISRUPTION
BRYONY WINN
Meet the Xconomists › Read More Xconomist Posts ›Xconomy Insight
*
Sponsored · Webinar SEPT. 15 – CHALLENGES OF IMPLEMENTING INNOVATION IN DRUG DISCOVERY& DEVELOPMENT
Phenotypic Screening & Profiling to Understand a Compound's DiseaseImpact
Eurofins Discovery
*
From Our Editors · Podcast XCELERATING LIFE SCIENCES SAN FRANCISCO: THE HIGHLIGHTS PODCAST The AI, Big Data, and R&D Boom*
Xconomy Insight · Special Report HOW TO JUMP 5 UNFORESEEN HURDLES TO BIOTECH SUCCESS – STARTUPSOURCEBOOK
Insights, wisdom, and inspiration on what it takes*
STARTUPS
*
LIFE SCIENCES
UNDERWRITERS AND PARTNERS*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
XCONOMY ON DEMAND
WE OFFER A NUMBER OF WAYS TO SUBSCRIBE FOR FREE!Subscribe Now
* Home
* Privacy Policy
* Security Disclosures* About
* Contact Us
* Archives
* Advertise
* Subscribe for Free 2007-2021, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0